CEO Devdatt Kurdikar was paid $9,400,088 in fiscal year 2025, the 59th percentile of its disclosed peer group (SEC filing 0001140361-25-046025 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$9,400,088 Devdatt Kurdikar total, FY2025 | 59th CEO pay percentile vs peers | 124:1 CEO-to-median pay ratio | 98.38% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
EMBC's next annual pay disclosure, estimated December 18, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Devdatt Kurdikar | $976,923 | $0 | $7,000,008 | $0 | $1,399,540 | $0 | $23,617 | $9,400,088 |
| Director, Chief Executive Officer and President | ||||||||
| Jake Elguicze | 603,077 | 0 | 2,300,025 | 0 | 504,165 | 0 | 51,782 | 3,459,049 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Jeff Mann | 600,769 | 0 | 1,900,032 | 0 | 470,554 | 0 | 34,017 | 3,005,372 |
| Senior Vice President, General Counsel and Product Development | ||||||||
| Shaun Curtis | 580,447 | 14,898 | 900,031 | 0 | 391,458 | 0 | 178,202 | 2,065,037 |
| Senior Vice President, Global Manufacturing, Supply Chain and Quality | ||||||||
| Jean Casner | 480,385 | 0 | 875,010 | 0 | 320,682 | 0 | 53,916 | 1,729,993 |
| Senior Vice President, Chief Human Resources Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Devdatt Kurdikar | $9,400,088 | — | — | — |
| Jake Elguicze | 3,459,049 | 3,116,275 | 2,583,449 | ↑ +342,774 |
| Jeff Mann | 3,005,372 | 2,593,218 | 2,204,768 | ↑ +412,154 |
| Shaun Curtis | 2,065,037 | 1,684,275 | 1,490,407 | ↑ +380,762 |
| Jean Casner | 1,729,993 | 1,341,235 | — | ↑ +388,758 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Embecta Corp.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper EMBC reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Embecta Corp. Peer Teardown Report
$9,400,088 Devdatt Kurdikar total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 1, 2026 · Source: 0001140361-25-046025 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for EMBC
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order EMBC
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses EMBC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EMBC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Embecta Corp. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Carrie L. Anderson | Independent Director | $317,004 |
| Christopher R. Reidy | Independent Director | $331,754 |
| Claire Pomeroy | Independent Director | $333,004 |
| David F. Melcher | Chair of the Board | $437,019 |
| David J. Albritton | Independent Director | $312,004 |
| Karen N. Prange | Independent Director | $328,004 |
| Milton M. Morris | Independent Director | $317,004 |
| Robert (Bob) J. Hombach | Independent Director | $332,004 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christopher R. Reidy | Director | 2026-02-11 | A | 22,841 | $0 | $0 | Common | Form 4 ↗ |
| Claire Pomeroy | Director | 2026-02-11 | A | 22,841 | 0 | 0 | Common | Form 4 ↗ |
| Karen N. Prange | Director | 2026-02-11 | A | 22,841 | 0 | 0 | Common | Form 4 ↗ |
| Robert (Bob) J. Hombach | Director | 2026-02-11 | A | 22,841 | 0 | 0 | Common | Form 4 ↗ |
| Milton M. Morris | Director | 2026-02-11 | A | 22,841 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Anderson | Director | 2026-02-11 | A | 22,841 | 0 | 0 | Common | Form 4 ↗ |
| Anthony M. Roth | VP, Chief Accounting Officer | 2026-06-01 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Jean Casner | Chief Human Resources Officer | 2026-08-09 | D | 1,480 | 4 | 6,542 | Common | Form 4 ↗ |
| Robert (Bob) J. Hombach | Director | 2026-08-12 | A | 45,000 | 5 | 223,848 | Common | Form 4 ↗ |
| Jeff Mann | Pres, Pharm Svc&Prod Mgmt, CLO | 2026-08-12 | A | 20,000 | 5 | 99,800 | Common | Form 4 ↗ |
| Devdatt Kurdikar | Director | 2026-08-12 | A | 30,000 | 5 | 140,937 | Common | Form 4 ↗ |
| Jake Elguicze | SVP and CFO | 2026-08-12 | A | 20,000 | 5 | 93,360 | Common | Form 4 ↗ |
| Milton M. Morris | Director | 2026-09-04 | D | 6,293 | 6 | 36,971 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Shaun Curtis | PSU | 2024-11-26 | 12,033 | 24,065 | — | 48,130 | $450,016 |
| Shaun Curtis | RSU | 2024-11-26 | — | — | 24,065 | — | 450,016 |
| Jean Casner | RSU | 2024-11-26 | — | — | 23,396 | — | 437,505 |
| Devdatt Kurdikar | RSU | 2024-11-26 | — | — | 187,166 | — | 3,500,004 |
| Jean Casner | PSU | 2024-11-26 | 11,698 | 23,396 | — | 46,792 | 437,505 |
| Jake Elguicze | RSU | 2024-11-26 | — | — | 61,498 | — | 1,150,013 |
| Jake Elguicze | PSU | 2024-11-26 | 30,749 | 61,498 | — | 122,996 | 1,150,013 |
| Jeff Mann | RSU | 2024-11-26 | — | — | 50,803 | — | 950,016 |
| Devdatt Kurdikar | PSU | 2024-11-26 | 93,583 | 187,166 | — | 374,332 | 3,500,004 |
| Jeff Mann | PSU | 2024-11-26 | 25,402 | 50,803 | — | 101,606 | 950,016 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Shaun Curtis | $450,016 | $450,016 | $0 | 50.0% |
| Jean Casner | 437,505 | 437,505 | 0 | 50.0% |
| Devdatt Kurdikar | 3,500,004 | 3,500,004 | 0 | 50.0% |
| Jake Elguicze | 1,150,013 | 1,150,013 | 0 | 50.0% |
| Jeff Mann | 950,016 | 950,016 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Devdatt Kurdikar | RSU | 195,648 | — | $2,760,593 |
| Jean Casner | RSU | 24,458 | — | 345,102 |
| Devdatt Kurdikar | PSU | 195,648 | — | 2,760,593 |
| Devdatt Kurdikar | RSU | 194,561 | — | 2,745,256 |
| Devdatt Kurdikar | RSU | 129,711 | — | 1,830,222 |
| Devdatt Kurdikar | RSU | 83,233 | — | 1,174,418 |
| Jake Elguicze | Option | 26,044 | 28.31 | — |
| Jake Elguicze | PSU | 64,287 | — | 907,090 |
| Jake Elguicze | RSU | 64,287 | — | 907,090 |
| Jeff Mann | RSU | 33,211 | — | 468,607 |
| Jake Elguicze | RSU | 62,263 | — | 878,531 |
| Jeff Mann | PSU | 53,107 | — | 749,340 |
| Jeff Mann | RSU | 53,107 | — | 749,340 |
| Jeff Mann | RSU | 49,811 | — | 702,833 |
| Jake Elguicze | RSU | 41,513 | — | 585,748 |
| Devdatt Kurdikar | RSU | 27,750 | — | 391,553 |
| Shaun Curtis | PSU | 25,157 | — | 354,965 |
| Shaun Curtis | RSU | 25,157 | — | 354,965 |
| Jean Casner | PSU | 24,458 | — | 345,102 |
| Jake Elguicze | RSU | 24,214 | — | 341,660 |
| Devdatt Kurdikar | Option | 33,001 | 31.4 | — |
| Shaun Curtis | RSU | 20,239 | — | 285,572 |
| Jeff Mann | RSU | 19,674 | — | 277,600 |
| Jean Casner | RSU | 16,503 | — | 232,857 |
| Jeff Mann | RSU | 6,560 | — | 92,562 |
| Shaun Curtis | RSU | 13,497 | — | 190,443 |
| Jean Casner | RSU | 11,008 | — | 155,323 |
| Shaun Curtis | RSU | 9,080 | — | 128,119 |
| Jake Elguicze | RSU | 8,073 | — | 113,910 |
| Jean Casner | RSU | 3,760 | — | 53,054 |
| Shaun Curtis | RSU | 3,028 | — | 42,725 |
| Devdatt Kurdikar | Option | 52,080 | 28.31 | — |
| Shaun Curtis | Option | 3,014 | 28.31 | — |
| Jeff Mann | Option | 26,044 | 28.31 | — |
Our compensation program serves as a key vehicle for attracting, retaining and motivating top talent. We believe that attracting and retaining superior talent and rewarding performance is key to delivering long-term stockholder returns and that a competitive compensation program is critical to that end.
| CEO STI target (% of salary) | 127% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Korn Ferry |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-02-11 | 47,665,209 | 786,816 | 74,488 | 98.38% | Passed |
| 2025 | 2025-02-12 | 47,859,210 | 1,318,677 | 60,059 | 97.32% | Passed |
| 2024 | 2024-02-07 | 46,011,161 | 586,124 | 71,375 | 98.74% | Passed |
| 2023 | 2023-02-09 | 49,015,194 | 1,711,764 | 71,716 | 96.63% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-02-11 | 98.38%a |
| 2025 | 2025-02-12 | 97.32%b |
| 2024 | 2024-02-07 | 98.74%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted as votes cast and therefore will have no effect on determining whether the required majority vote has been attained.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted as votes cast and therefore will have no effect on determining whether the required majority vote has been attained.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted as votes cast and therefore will have no effect on determining whether the required majority vote has been attained.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 124 : 1 |
|---|---|
| CEO total compensation | $9,400,088 |
| Median employee compensation | $75,558 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David F. MelcherIndependent · Board Chair · Not standing for re-election | $140,000 | $290,019 | — | — | $7,000 | $437,019 |
| Claire PomeroyIndependent · Corporate Governance and Nominating | 96,000 | 230,004 | — | — | 7,000 | 333,004 |
| Robert (Bob) J. HombachIndependent · TQRC | 100,000 | 230,004 | — | — | 2,000 | 332,004 |
| Christopher R. ReidyIndependent · TQRC | 96,000 | 230,004 | — | — | 5,750 | 331,754 |
| Karen N. PrangeIndependent · Audit · Compensation and Management Development (Chair) · Corporate Governance and Nominating | 96,000 | 230,004 | — | — | 2,000 | 328,004 |
| Carrie L. AndersonIndependent · TQRC | 80,000 | 230,004 | — | — | 7,000 | 317,004 |
| Milton M. MorrisIndependent · Compensation and Management Development | 80,000 | 230,004 | — | — | 7,000 | 317,004 |
| David J. AlbrittonIndependent | 80,000 | 230,004 | — | — | 2,000 | 312,004 |
| Devdatt (Dev) KurdikarEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $80,000 |
|---|---|
| Annual equity retainer | $230,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 16,000 / 16,000 |
| Stock ownership guideline | $400,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $768,000 |
| Equity awards (grant-date value) | $1,900,047 |
| All other compensation | $39,750 |
| Total cost of the board | $2,707,797 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Embecta Corp. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Embecta Corp..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Insulet Corporation | 2025 | Ashley McEvoy | $729,808 | $12,958,850 | $2,999,913 | $2,031,562 | $18,858,968 |
| 2 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 3 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 4 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 5 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 6 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 7 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 8 | Embecta Corp. | 2025 | Devdatt Kurdikar | 976,923 | 7,000,008 | 0 | 1,399,540 | 9,400,088 |
| 9 | Integra LifeSciences Holding Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | Integer Holdings Corporation | 2025 | Joseph Dziedzic | 1,235,000 | 5,999,951 | 0 | 1,323,766 | 8,671,332 |
| 11 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 12 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 13 | CONMED Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 14 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 15 | West Pharmaceutical Services, Inc. | 2025 | Eric Green | 1,177,290 | 3,327,048 | 1,108,961 | 1,471,613 | 7,190,876 |
| 16 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 17 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 18 | ICU Medical, Inc. | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Embecta Corp. | 110.2% | not disclosed | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| CONMED Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| ICU Medical, Inc. | 150% | PSU 50 · RSU 50 | No | Compensia |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Integer Holdings Corporation | 85.75% | PSU 66 · RSU 34 | Yes — Relative TSR versus peer group | FW Cook |
| Integra LifeSciences Holding Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| West Pharmaceutical Services, Inc. | 100% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Devdatt Kurdikar | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Executive Compensation”. As printed: 9,400,088. Filing ↗machine: r2 · c25 · span 968408–968417 |
| 2 | Section 01, Jake Elguicze | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Executive Compensation”. As printed: 3,459,049. Filing ↗machine: r5 · c25 · span 983597–983606 |
| 3 | Section 01, Jeff Mann | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Executive Compensation”. As printed: 3,005,372. Filing ↗machine: r11 · c25 · span 1013910–1013919 |
| 4 | Section 01, Shaun Curtis | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Executive Compensation”. As printed: 2,065,037. Filing ↗machine: r8 · c25 · span 998661–998670 |
| 5 | Section 01, Jean Casner | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Executive Compensation”. As printed: 1,729,993. Filing ↗machine: r14 · c25 · span 1029321–1029330 |
| 6 | Section 03, Shaun Curtis PSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r10 · c16 · span 1138875–1138881 |
| 7 | Section 03, Shaun Curtis RSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r10 · c16 · span 1138875–1138881 |
| 8 | Section 03, Jean Casner RSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r16 · c16 · span 1168222–1168228 |
| 9 | Section 03, Devdatt Kurdikar RSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r4 · c16 · span 1109682–1109689 |
| 10 | Section 03, Jean Casner PSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r16 · c16 · span 1168222–1168228 |
| 11 | Section 03, Jake Elguicze RSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r7 · c16 · span 1124255–1124261 |
| 12 | Section 03, Jake Elguicze PSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r7 · c16 · span 1124255–1124261 |
| 13 | Section 03, Jeff Mann RSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r13 · c16 · span 1153610–1153616 |
| 14 | Section 03, Devdatt Kurdikar PSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r4 · c16 · span 1109682–1109689 |
| 15 | Section 03, Jeff Mann PSU | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Narrative disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t140 · r13 · c16 · span 1153610–1153616 |
| 16 | Section 07, pay ratio | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “CEO Pay Ratio”. As printed: 124 : 1. Filing ↗machine: span 1650043–1650046 |
| 17 | Section 08, David F. Melcher | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 437,019. Filing ↗machine: span 521485–521660 |
| 18 | Section 08, Claire Pomeroy | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 333,004. Filing ↗machine: span 538802–538977 |
| 19 | Section 08, Robert (Bob) J. Hombach | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 332,004. Filing ↗machine: span 533022–533197 |
| 20 | Section 08, Christopher R. Reidy | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 331,754. Filing ↗machine: span 530166–530341 |
| 21 | Section 08, Karen N. Prange | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 328,004. Filing ↗machine: span 541096–541270 |
| 22 | Section 08, Carrie L. Anderson | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 317,004. Filing ↗machine: span 527271–527446 |
| 23 | Section 08, Milton M. Morris | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 317,004. Filing ↗machine: span 535913–536088 |
| 24 | Section 08, David J. Albritton | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 312,004. Filing ↗machine: span 524378–524553 |
| 25 | Section 08, Devdatt (Dev) Kurdikar | DEF 14A | 2025-12-18 | 0001140361-25-046025 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, Christopher R. Reidy 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Claire Pomeroy 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Karen N. Prange 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Robert (Bob) J. Hombach 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Milton M. Morris 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Carrie L. Anderson 2026-02-11 | Form 4 | 2026-02-13 | 0000947871-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Anthony M. Roth 2026-06-01 | Form 4 | 2026-06-02 | 0000947871-26-000597 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Jean Casner 2026-08-09 | Form 4 | 2026-08-11 | 0000947871-26-000779 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Robert (Bob) J. Hombach 2026-08-12 | Form 4 | 2026-08-13 | 0000947871-26-000786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Jeff Mann 2026-08-12 | Form 4 | 2026-08-13 | 0000947871-26-000787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Devdatt Kurdikar 2026-08-12 | Form 4 | 2026-08-13 | 0000947871-26-000789 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Jake Elguicze 2026-08-12 | Form 4 | 2026-08-13 | 0000947871-26-000788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Milton M. Morris 2026-09-04 | Form 4 | 2026-09-08 | 0000947871-26-000859 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 06, 2026 vote | Form 8-K | 2026-02-13 | 0000947871-26-000153 | Item 5.07 · say-on-pay result. As reported: 98.38% (votes for as printed: 47,665,209). Filing ↗ |
| 40 | Section 06, 2025 vote | Form 8-K | 2025-02-14 | 0000947871-25-000163 | Item 5.07 · say-on-pay result. As reported: 97.32% (votes for as printed: 47,859,210). Filing ↗ |
| 41 | Section 06, 2024 vote | Form 8-K | 2024-02-09 | 0000947871-24-000101 | Item 5.07 · say-on-pay result. As reported: 98.74% (votes for as printed: 46,011,161). Filing ↗ |
| 42 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 43 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 44 | Section 09b board cost (computed) | Computed | — | — | Cash 768,000 + equity 1,900,047 + all other 39,750 = 2,707,797, summed across the director compensation table rows.machine: formula: Σ = 2,707,797 |
| 45 | Insulet Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 46 | ResMed Inc., Section 10b CEO total | DEF 14A | 2026-10-01 | 0000943819-26-000080 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. Filing ↗machine: span 1267106–1267116 |
| 47 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 48 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 49 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 50 | Nevro Corp., Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044100 | CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993 |
| 51 | Avanos Medical, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-027106 | CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. Filing ↗machine: r1 · c53 · span 1674377–1674386 |
| 52 | Embecta Corp. (subject), Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046025 | CEO total compensation as printed in Embecta Corp.'s own proxy. As printed: 9,400,088. Filing ↗machine: r2 · c25 · span 968408–968417 |
| 53 | Integra LifeSciences Holding Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0000917520-26-000015 | CEO total compensation as printed in Integra LifeSciences Holding Corporation's own proxy. As printed: 9,375,551. Filing ↗machine: r2 · c30 · span 880204–880213 |
| 54 | Integer Holdings Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001114483-26-000009 | CEO total compensation as printed in Integer Holdings Corporation's own proxy. As printed: 8,671,332. Filing ↗machine: t48 · r17 · c21 · span 738226–738235 |
| 55 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 56 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 57 | CONMED Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000816956-26-000047 | CEO total compensation as printed in CONMED Corporation's own proxy. As printed: 7,634,873. Filing ↗machine: r3 · c27 · span 1186564–1186573 |
| 58 | Orthofix Medical Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191716 | CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. Filing ↗machine: t96 · r4 · c16 · span 1472329–1472338 |
| 59 | West Pharmaceutical Services, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-026778 | CEO total compensation as printed in West Pharmaceutical Services, Inc.'s own proxy. As printed: 7,190,876. Filing ↗machine: t165 · r7 · c18 · span 1241781–1241790 |
| 60 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 61 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 62 | ICU Medical, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0000883984-26-000019 | CEO total compensation as printed in ICU Medical, Inc.'s own proxy. As printed: 6,452,042. Filing ↗machine: r2 · c24 · span 432290–432299 |
| 63 | Section 10a, Avanos Medical, Inc. reciprocity | DEF 14A | — | 0001104659-26-027106 | Avanos Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 64 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 65 | Section 10a, Orthofix Medical Inc. reciprocity | DEF 14A | — | 0001193125-26-191716 | Orthofix Medical Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 66 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 67 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 68 | Section 10a, Integer Holdings Corporation reciprocity | DEF 14A | — | 0001114483-26-000009 | Integer Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 69 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-26-000080 | ResMed Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 70 | Section 10a, West Pharmaceutical Services, Inc. reciprocity | DEF 14A | — | 0001104659-26-026778 | West Pharmaceutical Services, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 71 | Section 10a, CONMED Corporation reciprocity | DEF 14A | — | 0000816956-26-000047 | CONMED Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 72 | Section 10a, Integra LifeSciences Holding Corporation reciprocity | DEF 14A | — | 0000917520-26-000015 | Integra LifeSciences Holding Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 73 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 74 | Section 10a, Nevro Corp. reciprocity | DEF 14A | — | 0000950170-24-044100 | Nevro Corp.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 75 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 76 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 77 | Section 10a, Insulet Corporation reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corporation's most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
| 78 | Section 10a, ICU Medical, Inc. reciprocity | DEF 14A | — | 0000883984-26-000019 | ICU Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Embecta Corp.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Embecta Corp. Executive Compensation Report
$1,500